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Abstract
Purpose Administration of 5 million alloreactive natural
killer (NK) cells after low-dose chemo-irradiation cured
mice of 4T1 breast cancer, supposedly dose dependent. We
now explored the efficacy of bone marrow as alternative
in vivo source of NK cells for anti-breast cancer treatment,
as methods for in vitro clinical scale NK cell expansion are
still in developmental phases.
Methods Progression-free survival (PFS) after treatment
with different doses of spleen-derived alloreactive NK cells
to 4T1-bearing Balb/c mice was measured to determine a
dose–response relation. The potential of bone marrow as
source of alloreactive NK cells was explored using MHC-
mismatched mice as recipients of 4T1. Chemo-irradiation
consisted of 29 2 Gy total body irradiation and 200 mg/kg
cyclophosphamide. Antibody-mediated in vivo NK cell
depletion was applied to demonstrate the NK cell’s role.
Results Administration of 2.5 instead of 5 million allore-
active NK cells significantly reduced PFS, evidencing dose
responsiveness. Compared to MHC-matched receivers of
subcutaneous 4T1, fewer MHC-mismatched mice devel-
oped tumors, which was due to NK cell alloreactivity
because in vivo NK cell depletion facilitated tumor growth.
Application of low-dose chemo-irradiation increased
plasma levels of NK cell-activating cytokines, NK cell
activity and enhanced NK cell-dependent elimination of
subcutaneous tumors. Intravenously injected 4T1 was
eliminated by alloreactive NK cells in MHC-mismatched
recipients without the need for chemo-irradiation.
Conclusions Bone marrow is a suitable source of sufficient
alloreactive NK cells for the cure of 4T1 breast cancer.
These results prompt clinical exploration of bone marrow
transplantation from NK-alloreactive MHC-mismatched
donors in patients with metastasized breast cancer.
Keywords 4T1  Breast cancer  Immunotherapy 
Alloreactive NK cell  Hematopoietic stem cell
transplantation
Introduction
Mice with 4T1 breast cancer can be cured by transfer of 5
million alloreactive NK cells after a non-myeloablative
dose of total body irradiation and cyclophosphamide
(‘‘chemo-irradiation’’) [1]. NK cell alloreactivity is present
when tumor cells do not express the appropriate major
histocompatibility (MHC) alleles for one or more inhibi-
tory receptors of donor NK cells (i.e., ‘‘missing self’’
concept [2]), a situation that typically may occur when
using MHC-mismatched donors. Similar anti-cancer
effects exerted by transferred alloreactive NK cells have
been observed in mouse models for murine [3–6] and
human acute myeloid leukemia [7], and for human multiple
myeloma [8]. Indications that alloreactive NK cells may be
able to kill solid non-hematological tumor tissue comes
from a preclinical study where it had been demonstrated
that freshly isolated solid tumor tissue is only killed by NK
cells from alloreactive and not from non-alloreactive
donors [9]. Unequivocal evidence that transfer of
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alloreactive NK cells exerts an anti-cancer effect in patients
does not exist, either because the chemotherapy and/or
irradiation applied before the administration may have
resulted in increased progression-free survival or because
transferred NK cells are not, transiently or only in limited
numbers detectable in recipients [10]. It is for this reason
that many efforts are currently performed to produce large
amounts of NK cells for clinical application, and the suc-
cess of these approaches is yet to be awaited. As a dose–
response relation of the number of transferred alloreactive
NK cells and the anti-4T1 breast cancer effect had not been
demonstrated yet, we wanted to proof this formally in the
current study.
An alternative and clinically applicable source for
alloreactive NK cells are MHC-mismatched hematopoietic
cells. The advantages of this source are the guaranteed and
continuous production of NK cells that are alloreactive
toward the patient in case the patient does not express one
or more ligands for NK cell inhibitory receptors that are
present in the donor. In this setting, donor NK cells mature
under the influence of the MHC of the donor’s
hematopoietic system which directs the licensing of all NK
cells that bear inhibitory receptors for self-MHC resulting
in NK cell alloreactivity toward tumor cells of patients that
lack the appropriate MHC alleles [11–13]. The possible
benefit of this treatment is not hypothetical, as results of
retrospective clinical studies show that relapse rates in
patients with acute myeloid leukemia after MHC-mis-
matched hematopoietic stem cell transplantation (HSCT)
from NK-alloreactive donors are lower compared to the
results with non-NK-alloreactive donors under the condi-
tion of a low incidence of acute graft-versus-host disease
(GVHD) [14–19]. MHC-mismatched HSCT was, however,
until recently a very risky procedure due to a high treat-
ment-related mortality from opportunistic infections due to
a prolonged T cell deficiency state when deep T cell
depletion was applied to prevent GVHD [15, 20, 21].
However, the now widely used application of post-HSCT
cyclophosphamide (PT-CY) prevents prolonged T cell
deficiency, high infection rates, and GVHD, and this has
made MHC-mismatched HSCT a safe and feasible proce-
dure [22, 23]. NK-alloreactive MHC-mismatched HSCT
has never been tested for patients with breast cancer or any
other type of non-hematological cancer, and hence we
wanted to study the curative potential of alloreactive NK
cells that had matured in 4T1 breast cancer-bearing mice.
As 4T1 is a rapidly growing tumor and because it takes
several months for NK cells to mature and become fully
functional after HSCT [13, 24], we employed a surrogate
model to mimic treatment of breast cancer-bearing mice
with HSCT from a NK-alloreactive MHC-mismatched
donor. In this model, MHC-mismatched mice that are NK
alloreactive toward 4T1 breast cancer were injected either
subcutaneously (s.c.) or intravenously (i.v). with 4T1 cells
representing primary and metastasized disease, respec-
tively, and followed for several weeks for tumor develop-
ment. In some experiments, a non-myeloablative dose of
cyclophosphamide and total body irradiation were applied
to study if these would increase NK cell-activating cyto-
kine plasma levels, NK cell activation, and the anti-tumor
effect, and in vivo NK cell depletion by antibodies was
used to demonstrate the indispensability of NK cells for the
anti-tumor effect.
Materials and methods
Cells, animals, and tumor models
4T1 breast cancer cell line of Balb/cfC3H origin [25] was
cultured in RPMI1640. Harvest was after 2 min
trypsinization, and 5 9 104 viable cells were injected
either s.c. or i.v. Balb/c (H-2d), C57BL/6 (‘‘B6,’’ H-2b),
(CBA 9 C57Bl/6)F1 (‘‘B6CBAF1,’’ H-2b/k) and (Balb/
c 9 C57Bl/6)F1 (‘‘CB6F1,’’ H-2b/d) mice were from Har-
lan Laboratories (Horst, the Netherlands) and housed under
specified pathogen-free conditions. Mice were in follow-up
for at least 100 days after tumor induction and underwent
standard autopsy for the presence of lung and liver
metastases which we never found in mice that were cured
from their s.c. tumors. Balb/c mice that succumbed from
breast cancer regularly had metastases in lungs and liver,
while this was occasionally the case for B6CBAF1 mice
with s.c. tumors. All B6CBAF1 mice that died from i.v.
injected 4T1 tumor cells had pulmonary metastases.
For the study of a dose–response effect of transferred
NK cells, 4T1-bearing Balb/c mice were used. In the sec-
ond set of experiments where the anti-tumor effect of NK
cells that had endogenously matured from bone marrow in
the tumor-bearing host, we chose a model where MHC-
mismatched B6CBAF1 mice served as recipients of 4T1
breast cancer cells instead of transplanting MHC-mis-
matched HSC into Balb/c 4T1-bearing mice. This was
because the rapid growth of the 4T1 breast cancer cells,
even after chemo-irradiation, would not allow sufficient
time for the donor-derived alloreactive NK cells to become
mature and active. S.c. injected 4T1 was used as a model
for localized breast cancer, while i.v. injection of 4T1 cells
mimics the process of metastasis.
Chemo-irradiation
Chemo-irradiation was performed by 29 2 Gy TBI (PHI-
LIPS X-ray unit, 225 kV, 10 mA, dose-rate 66 cGy/min) at
8 and 9 days after tumor induction combined with 200 mg/
kg cyclophosphamide (Baxter Oncology GmbH, Halle,
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Germany) at day 9. This conditioning is non-myeloablative
in mice [26].
NK cell transfer
NK cell-enriched spleen cell batches were prepared from
single cell suspensions from the spleens of donor mice by
MACS negative selection (Miltenyi Biotec B.V., Utrecht,
the Netherlands); a typical NK cell dose of 5 9 106 NK
cells contained approximately 0.06 9 106 T cells. We
made use of a difference in frequency of NK cells with
alloreactive activity toward H-2d target cells of various
strains of mice as dictated by their H-2 type. Whereas all
NK cells of B6 (H-2b) and B6CBAF1 (H-2b/k) mice are
alloreactive toward H-2d target cells (i.e., ‘‘full-alloreac-
tive’’), only half of the NK cells in CB6F1 (H-2b/d) mice
are (i.e., ‘‘half-alloreactive’’). This difference has been
shown to translate in faster in vivo elimination of H-2d-
positive target cells by full-alloreactive NK cells than by
half-alloreactive NK cells [1, 27, 28]. Besides, CB6F1 T
cells are tolerant to Balb/c tissue and are therefore not able
to act as alloimmune effector cells.
In vivo NK cell depletion
In vivo NK cell depletion was performed in two consecu-
tive experiments by intraperitoneal (i.p.) injection with
either anti-AsialoGM1 or anti-NK1.1. We chose for using
both antibodies to be sure that the effect of antibody
administration on the anti-tumor effect could most surely
be attributed to the depletion of NK cells only, because
subsets of T cells express AsialoGM1 and many NKT cells
express NK1.1 [29, 30]. 200 ll of mouse-specific poly-
clonal rabbit anti-AsialoGM-1 (Wako Pure Chemical
Industries) [31] was administered intraperitoneally at days
0, 5, and 10 after tumor induction. In the next experiment,
500 lg anti-NK1.1 (PK136, BD Pharmingen) [29, 32] was
administered intraperitoneally at day 0, 5, and then every
other 5 days until the death of the mice or the end of the
experiment, because we realized from the results of the
experiment with anti-AsialoGM1 that this should have
been administered during the whole experiment too. The
NK cell depletion efficacy had been previously checked in
three mice for each antibody by measuring the NK cell
content in blood and spleen just before the time of second
administration of either anti-AsialoGM1 or anti-NK1.1;
NK cell depletion amounted approx. 1 log in all.
Plasma NK cell-activating cytokine level
measurements
Plasma was prepared from blood drawn from just priorly
euthanatized mice. IL-2, IL-15, IL-18, and IL-21 plasma
levels were determined by standard ELISA (R&D
Systems).
Flowcytometry
All flowcytometry analyses were performed using a BD
FACS CantoII flow cytometer using BD DIVA software.
In vivo NK cell depletion efficiency was by staining spleen
single-cell suspensions with the mouse-specific antibodies
CD3e PerCP, and CD49b APC after incubation with NMS.
NK cell activation was determined with antibodies specific
for CD69, CD107a, TRAIL, and FasL. 7-AAD or Pi was
for excluding non-viable cells, and all flowcytometry
analyses were exclusively on viable cells. All monoclonal
antibodies and 7-AAD were from BD Biosciences, and Pi
was from Invitrogen.
Ethical approval
The local animal ethical committee had approved all the
mouse experiments.
Statistics
Survival curves were composed using the Kaplan–Meier
method and compared with the Mantel–Cox log-rank test.
Differences in cytokine levels and expression of NK cell
activation markers after chemo-irradiation were compared
with non-chemo-irradiated mice using the two-tailed Wil-
coxon’s signed-rank sum test. Values are presented as
mean ± SEM. In all cases, differences were considered
statistically significant when probability (p) values were
less than 0.05.
Results
High numbers of alloreactive NK cells are required
to cure 4T1 breast cancer
To demonstrate dose dependency of the anti-4T1 breast
cancer effect by transferred alloreactive NK cells, 4T1-
bearing Balb/c mice were treated with chemo-irradiation at
8 and 9 days after 4T1 injection followed by i.v. injection
of 5 million NK cells from various donors that differed
with respect to the percentage of NK cell alloreactivity
toward Balb/c-type cells (as described in ‘‘Materials and
methods’’ section). Long-lasting breast cancer-free survival
resulted in the vast majority (19 out of 20) of mice that
received 5 million NK cells from full-alloreactive B6 or
B6CBAF1 donors or 10 million NK cells from half-al-
loreactive CB6F1 mice (9 out of 10), while 90% of the
untreated mice died from tumor progression (p\ 0.001 for
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each treatment group, Fig. 1a). Although the administra-
tion of 5 million half-alloreactive CB6F1 NK cells
(equivalent to 2.5 million fully alloreactive NK cells)
resulted in cure in 6 out of 10 mice (p\ 0.01 compared to
untreated mice), its efficacy was statistically significantly
lower than in the three groups that received 5 million fully
alloreactive NK cells (i.e., either 5 million full-alloreactive
NK cells from either B6 or B6CBAF1 donors or 10 million
half-alloreactive NK cells from CB6F1 donors (p\ 0.01
when these three groups are compared with the PFS of
mice that received 5 million half-alloreactive NK cells
from CB6F1 donors, Fig. 1b). The results of administration
of 10 million half-alloreactive CB6F1 NK cells also
demonstrate that effective alloreactive NK cell therapy
does not require T cell alloreactivity, as CB6F1 T cells are
tolerant toward Balb/c-MHC type.
Our results show that fairly high numbers of alloreactive
NK cells are required for an effective anti-tumor response.
While the procedures for NK cell expansion that reliably
produces this high number of NK cells for clinical appli-
cation are improving over the last years, only a few look
promising but are still in the experimental phase. We
therefore studied if the number of NK cells that had been
produced and matured in MHC-mismatched tumor-re-
ceiving mice is sufficient to eliminate fast-growing 4T1
tumors, as a surrogate model for donor HSCT.
Fig. 1 Improved PFS is
alloreactive NK cell dose
dependent. Shown are PFS
curves of one experiment where
Balb/c mice were injected s.c.
with 4T1 breast cancer at day 0
and either left untreated or
treated with chemo-irradiation
at days 8 and 9 (indicated by the
symbol) followed by transfer
of NK cells from various mouse
strains with different numbers
of alloreactive NK cells toward
the Balb/c-type tumor at day 10
(indicated by the arrow, 10
mice per group; ‘‘b/d’’ (CB6F1)
mice have half the number of
alloreactive NK cells than ‘‘b’’
(B6) or ‘‘b/k’’ (B6CBAF1)
mice). a The PFS of each
treatment group separately and
b The PFS of recipients of equal
doses of alloreactive NK cells
grouped together. *Statistical
significant difference (p\ 0.01)
of the PFS of mice treated with
5 9 106 b/k NK cells compared
with PFS of mice without NK
cell treatment as well as with
the groups that received the
same 29 higher number of
alloreactive NK cells (i.e.,
5 9 106 b or b/k NK cells or
10 9 106 b/k NK cells) taken
together
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Alloreactive NK cells that had matured in the 4T1-
bearing host optimally eliminate MHC-mismatched
s.c. breast cancer after a low dose of chemo-
radiotherapy
S.c. injection of full-MHC-mismatched Balb/c-type 4T1
breast cancer cells in B6CBAF1 recipients surprisingly
induced tumors in many mice (Table 1, exp. nos. 1–4,
‘‘only s.c. 4T1 tumor induction’’ groups). When these
tumor-bearing mice were subsequently treated with the
same low-dose chemo-irradiation as used in the above and
previously described [1] transplantation experiments at 8
and 9 days after 4T1 tumor induction, tumor growth was
permanently arrested in the vast majority of mice (Table 1,
exp. nos. 2–4, ‘‘chemo-irradiation’’ groups). As we
hypothesized, but not yet had proven, that the observed
anti-tumor effect induced by chemo-irradiation relies on a
NK cell alloimmune response toward the tumor, we then
tested if in vivo NK cell depletion by antibodies would
impede the anti-tumor effect.
In the first experiment, in vivo NK cell depletion was
with anti-AGM1 administration during the first 2 weeks
after tumor induction (Table 1, exp. no. 3). Depletion of
AsialoGM1-positive cells resulted in an accelerated tumor
growth in the first week after tumor induction compared to
the untreated group: 10 of the 16 anti-AsialoGM1-treated
mice had developed a palpable tumor at day 8 (being the
first time point of chemo-irradiation) with tumor sizes
ranging from 37 to 85 mm3, compared to 6 of the 16 in the
untreated group where tumor sizes ranged from 5 to
10 mm3 (p\ 0.01 for tumor size) (Table 1, exp. no. 3). In
the anti-AsialoGM1-treated group, initially all palpable
tumors disappeared after chemo-irradiation, but then
reappeared and grew in 8 out of the 16 (7 had s.c. tumors, 1
deceased from pulmonary metastases). The mice treated
with chemo-irradiation without anti-AGM1 treatment had
similar tumor incidence and tumor size as in the untreated
group at day 8, but in only 3 out of 16 progressive s.c.
tumors (re-)appeared after chemo-irradiation, while 11 of
the 16 untreated mice died from s.c. progressive tumor
growth (n = 7) or from pulmonary metastases (n = 4).
The PFS was significantly better in the chemo-irradiated
group compared to the untreated ones (Fig. 2a, p\ 0.01),
while there was a trend for inferior PFS in the chemo-
irradiated and anti-AGM1-treated mice compared to those
treated with chemo-irradiation only (Fig. 2a, p = 0.09). It
was felt that the in vivo NK cell depletion in this experi-
ment might had lasted too short to unequivocally demon-
strate the role of NK cells in the chemo-irradiation-induced
anti-tumor effect.
In the second experiment with in vivo NK cell depletion,
anti-NK1.1 was administered throughout the whole
experiment (Table 1, exp. no. 4). Similar to the former NK
cell depletion experiment, the incidence of 4T1 breast
cancer in the first week after tumor induction was statisti-
cally significantly higher than in the ‘‘no further treatment’’
group (Table 1, exp. no. 4). As in the former depletion
experiment, tumors shrunk shortly after chemo-irradiation
but later reappeared in all but one (Table 1, exp. no. 4). In
the chemo-irradiated mice without anti-NK1.1 treatment,
only three died from tumor progression, while nine mice in
the untreated group succumbed from progressive breast
cancer. PFS of the chemo-irradiated and NK1.1-positive
cell-depleted group was inferior to the group of mice
Table 1 Low-dose chemo-irradiation enhances the anti-tumor effect of alloreactive NK cells that had developed and matured in the tumor-
bearing fully MHC-mismatched host
Exp.
no.
Treatment group (all had s.c. 4T1 breast
cancer)
Palpable tumor incidence
At day 8 p value At the end of the
experiment
p value
1. No further treatment 0/12 10/12
2. No further treatment 0/12 – 10/12 \0.01
Chemo-irradiation 0/12 Reference 2/12 Reference
3. No further treatment 6/16 – 11/16 0.01
Chemo-irradiation 5/16 Reference 3/16 Reference
Anti-AsialoGM1 NK cell depletion at days
0, 5, and 10 and chemo-irradiation
10/16 0.12 8/16 0.14
4. No further treatment 4/16 – 9/16 0.07
Chemo-irradiation 4/16 Reference 3/16 Reference
Anti-NK1.1 NK cell depletion from day 0
and chemo-irradiation
12/16 0.01 13/16 \0.01
Palpable s.c. 4T1 breast cancer incidence as measured at day 8 (i.e., the day of onset of chemo-irradiation in the appropriate groups) and at the
end of the experiment (130 days in experiments 1–3, 100 days in experiment 4)
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treated with chemo-irradiation only (Fig. 2b, p\ 0.01) and
to the ‘‘no further treatment’’ group (Fig. 2b, p\ 0.01),
and PFS of chemo-irradiated mice was better than that of
the untreated mice (p = 0.03).
Taken together, these results demonstrate the indis-
pensable role of NK cells both in delaying tumor pro-
gression and in chemo-radiation-induced eradication of s.c.
4T1 breast cancer in fully MHC-mismatched B6CBAF1
mice.
Low-dose CY1TBI results in increased plasma
levels of NK cell-activating cytokines as well
as in NK cell activation
Plasma levels of the NK cell-activating cytokines IL-2,
IL-15, IL-18, and IL-21 [33] increased substantially
within the first 2 days after CY?TBI compared to their
plasma levels in 4T1 tumor-bearing mice not subjected to
chemo-irradiation (Fig. 3). Thereafter, cytokine plasma
concentrations steadily decreased. To investigate if this
increased plasma levels of cytokines is accompanied with
NK cell activation, the activation status of splenic NK
cells, as measured by their CD69 [34], TRAIL, and FasL
expression [35] and degranulation status (by surface
CD107a expression) [36], was also determined at the
same time points (Fig. 4). For CD69, we found statisti-
cally significant increased expression already at the first
time point, i.e., 1 h after the 2nd cyclophosphamide dose
and TBI, that persisted, with a short lasting drop, till the
last measurement point at 48 h after the 2nd cyclophos-
phamide dose and TBI. A statistically significant increase
in the percentage of degranulating NK cells and in
TRAIL expression was evident from 24 h after the 2nd
cyclophosphamide dose and TBI. FasL expression had
doubled on all NK cells at all test points (p\ 0.001, data
not shown).
Fig. 2 NK cells mediate s.c.
injected 4T1 breast cancer
elimination in MHC-
mismatched hosts after chemo-
irradiation. PFS curves of two
separate experiments where
B6CBAF1 mice were s.c.
injected with 4T1 breast cancer
cells at day 0 followed by either
no further treatment (n = 16),
chemo-irradiation at days 8 and
9 (n = 16, indicated by the
symbol), AsialoGM1 depletion
[a n = 16, anti-AGM1 applied
(arrows)during the first
2 weeks, exp. A] or NK1.1
depletion [b n = 16, anti-NK1.1
applied (arrows) during whole
experiment], in both
experiments combined with
chemo-irradiation at days 8 and
9. All events were breast
cancer-related deaths.
Statistically significant
differences or trends of PFS
compared to the chemo-
irradiation groups are indicated
by *p\ 0.01, ¥p = 0.03, and
§p = 0.09
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Low-dose CY1TBI is not required for NK cell-
mediated in vivo elimination of i.v. injected MHC-
mismatched breast cancer cells
As i.v. injection of tumor cells mimics the process of
blood-born pulmonary metastasis, we tested whether
alloreactive NK cells are able to prevent metastasis. For
this purpose, we again used the fully MHC-mismatched
B6CBAF1 recipient model. I.v. injection of 4T1 breast
cancer in half-MHC-matched CB6F1 recipients resulted in
pulmonary metastases in all mice, while none of the
B6CBAF1 mice developed any pulmonary distress during
130 days of follow-up nor lung metastases at autopsy
(Table 2, exp. no. 5).
We then applied in vivo NK cell depletion by anti-
AGM1 or anti-NK1.1 to test whether the prevention of
pulmonary metastasis in the MHC-mismatched B6CBAF1
mice resulted from NK cell activity. Short-term AGM1-
postive cell depletion almost statistically significantly
increased mortality (Table 2, exp. no. 6) and statistically
significantly decreased PFS compared to untreated tumor-
Fig. 3 Chemo-irradiation leads to increased plasma levels of NK
cell-activating cytokines. Plasma levels of IL-2, IL-15, IL-18, and IL-
21 were measured at different time points after treatment of 4T1
tumor-bearing B6CBAF1 mice with CY?TBI, as indicated. Per time
point the median plasma level, and SEM are shown of five mice per
time point. The increases in plasma levels were highly statistically
significant (p\ 0.001) compared to non-chemo-irradiated mice for
all four measured cytokines at the first three time points and
statistically significant (p\ 0.01) for IL-15, IL-18, and IL-21 at the
two last time points
Fig. 4 Chemo-irradiation results in activation of NK cells. NK cell
activation was measured by increased CD69 and TRAIL expression
and by increased degranulation (cell surface CD107a expression) of
splenic NK cells at different time points after treatment of 4T1 tumor-
bearing B6CBAF1 mice with CY?TBI, as indicated. NK cells were
identified as CD3-negative and CD49b-positive lymphocytes. a The
percentages (and SEM) of NK cells positive for CD69, CD107a, and
TRAIL of five mice per time point: 9 days after 4T1 tumor induction
without treatment with CY?TBI, and at successive time points after
CY?TBI. §p\ 0.05, £p\ 0.01, *p\ 0.001 compared with 9 days
after 4T1 tumor induction without chemo-irradiation. b Examples of
FACS plots of CD69, CD107a, and TRAIL expression of splenic NK
cells of individual 4T1 tumor-bearing mice at the time points
indicated
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Table 2 Alloreactive NK cells prevent pulmonary metastasis of i.v. injected 4T1 breast cancer cells in the fully MHC-mismatched host
Exp. no. Treatment group (all had i.v.
4T1 tumor injection)
Recipient mouse strain Mortality from
pulmonary metastases
p value
5. No further treatment CB6F1 10/10 Reference
No further treatment B6CBAF1 0/11 \0.01
6. No further treatment B6CBAF1 2/16 Reference
Anti-AsialoGM1 NK cell depletion at days
0, 5, and 10
B6CBAF1 8/16 0.06
7. No further treatment B6CBAF1 3/16 Reference
Anti-NK1.1 NK cell depletion from day 0
until the end of the experiment
B6CBAF1 12/15 \0.01
Pulmonary metastases were evident by development of severe pulmonary distress requiring sacrifice. Follow-up time was 130 days after 4T1 i.v.
injection in exp. nos. 5 and 6, and 100 days in exp. no. 7
Fig. 5 NK cells mediate i.v.
injected 4T1 breast cancer
elimination in MHC-
mismatched hosts. PFS curves
of two separate experiments
where B6CBAF1 mice were
injected with 4T1 breast cancer
cells i.v. at day 0 followed by
either no further treatment
(n = 16) or AsialoGM1
depletion [a n = 16, anti-
AGM1 applied (arrows) during
the first 2 weeks] or NK1.1
depletion [b n = 15, anti-NK1.1
applied (arrows) during whole
experiment]. All events were
breast cancer-related deaths.
Statistically significant
differences or trends of PFS
compared to the ‘‘no further
treatment’’ groups are indicated
by }p\ 0.001 and •p = 0.02
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injected mice (Fig. 5a, p = 0.02; all deceased mice had
lung metastases at autopsy). Similarly, administration of
anti-NK1.1 every other 5 days from the time of i.v. tumor
injection until the day of sacrifice or the end of the
observation time resulted in a statistically significant
decreased survival (Table 2, exp. no. 7) and decreased PFS
(Fig. 5b, p\ 0.001). These data demonstrate that allore-
active NK cells are a prerequisite for elimination of i.v.
injected H-2-mismatched 4T1 breast cancer cells.
Discussion
In this study, we demonstrated a dose–response relation
between adoptively transferred NK cells from NK-allore-
active donors and the anti-tumor effect as well as the dis-
pensability of alloreactive T cells in the 4T1 mouse breast
cancer model. The human equivalent of the minimally
required number of full-alloreactive NK cells per mouse
(5 million for a mouse weighing 20 g amounts 0.25 9 109/
kg) would be 18.75 9 109 for a patient weighing 75 kg.
This number can never be harvested from a donor in a
single procedure and necessitates in vitro NK cell expan-
sion. Each individual mouse and man bears NK cell subsets
expressing different inhibitory and activating receptors.
Two preconditions determine if a given donor NK cell is
alloreactive: (1) membrane expression of iKIR specific for
a ligand that is present in the donor and absent in the
patient (i.e., certain MHC class I alleles) and (2) no
NKG2A expression (inhibitory receptor binding ubiqui-
tously expressed HLA-E that is not subject to allelic dif-
ferences with respect to binding to NKG2A). Additional
prerequisites for successful clinical application of expan-
ded NK cells are sufficient numbers and absence of donor
T cells causing severe GVHD. At present, the vast majority
of the laboratories working on clinical grade expansion of
NK cells do not unequivocally demonstrate that their NK
cell products meet all four prerequisites [37–49]. Only
recently a report was published on a successful though
laborious expansion procedure in the presence of mem-
brane-bound IL-21, which resulted in preserved KIR
expression and NKG2A absence [50]. Feasibility of the
clinical application of this NK cell product is yet to be
awaited. It remains, in general, also to be seen, if a single
administration of alloreactive NK cells which results in
only a transient engraftment is as effective in patients like
in our mouse model. This then justifies the exploration of
alternative ways to apply NK cells, especially when
resulting in the permanent presence of alloreactive NK
cells in the patient.
One such an alternative strategy is to apply HSCT from
NK-alloreactive MHC-mismatched donors as a permanent
source of NK cells, which is nowadays a fairly safe
procedure when PT-CY is applied [22, 23]. Reports on
MHC-mismatched HSCT from NK-alloreactive donors all
point toward a benefit with respect to leukemia-free sur-
vival in settings with a low incidence of acute GVHD
[15–17, 51, 52], and the role of alloreactive NK cells in this
setting is underscored by the fact that these cells are fully
functional within a few months after HSCT
[11–13, 53, 54]. Advantages of NK cell therapy by MHC-
mismatched HSCT are that it results in a permanent pro-
duction of alloreactive NK cells, as the latter quality hinges
on the origin of the hematopoietic cells (in this case the
donor’s) among which they mature [11–13]. In contrast,
adoptively transferred NK cells will probably lose their
alloreactive quality within days due to exposure to the
MHC-disparate patient’s hematopoietic system [55–57].
In this study, treatment with NK-alloreactive MHC-
mismatched HSCT of a breast cancer patient was mim-
icked using a MHC-mismatched host as recipient of 4T1
breast cancer, because the 4T1’s far more rapid tumor
growth than human breast cancer results in death weeks
before the donor bone marrow would have produced
enough functional NK cells. We demonstrated that both s.c.
and i.v. injected 4T1 breast cancer is eradicated by AGM1-
and NK1.1-positive cells. As only NK cells share both
characteristics [58, 59] and because NK cells alone are
sufficient for cure in the NK cell transfer model [1] [and
this manuscript], it is apparent that the anti-tumor effect
resulted from the MHC-mismatched host’s activated NK
cells.
The elimination of i.v. injected tumor cells (including
tumorigenic cells) by the NK cells of the NK-alloreactive
recipient was efficient and did not require further treat-
ment. This indicates that breast cancer metastasis in
patients after NK-alloreactive MHC-mismatched HSCT
may be prevented by the circulating donor-derived NK
cells. For extra-vascular tumor sites, additional treatment
with low-dose chemo-irradiation seems warranted for NK
cell-mediated elimination. This indicates that chemo-ir-
radiation may be required in patients with metastasized
breast cancer when functional donor-derived NK cells
have been produced several months after NK-alloreactive
MHC-mismatched HSCT. During the time of NK cell
repertoire constitution, tumor growth should be prevented
by the application of myeloablative conditioning before
MHC-mismatched HCSCT [60] which has shown to be
feasible even in heavily pretreated patients [61], and by
hormonal and/or anti-HER2neu therapies when
appropriate.
Puzzling is that adoptive transfer of sufficient numbers
of CB6F1 semi-MHC-mismatched NK cells cures Balb/c
mice from 4T1 breast cancer, while s.c. and i.v. injection of
4T1 in CB6F1 mice invariably results in high tumor-in-
duced mortality even when chemo-irradiation is applied in
Breast Cancer Res Treat (2017) 161:421–433 429
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contrast to the results in fully MHC-mismatched B6CBAF1
mice. This discrepancy may be a matter of the number of
actual alloreactive NK cells toward the Balb/c-type tumor.
The fact that half-MHC-mismatched HSCT from NK-al-
loreactive donors is very effective in preventing leukemia
relapse in patients [15–17, 51, 52] brings promise that the
number of alloreactive NK cells several months after half-
MHC-mismatched HSCT will also be sufficient for the
elimination of residual breast cancer after the conditioning
before HSCT and the subsequent application of chemo-
irradiation.
Various mechanisms may contribute to the potentia-
tion by chemo-irradiation of the NK cell-mediated anti-
tumor effect. One may be related to the ascertained NK
cell activation either by the observed increase in plasma
levels of pro-inflammatory and NK cell-activating
cytokines, possibly related to the chemo-irradiation-in-
duced reduction in lymphocyte number [62–65], and/or
by translocation of commensal gut flora and LPS [63].
Although the number of NK cells also decreases after
chemo-irradiation [63], their numbers may still have
remained sufficiently high to eradicate 4T1 breast cancer
upon their cytokine-induced activation, analogous to the
observation that i.v. injected MHC-mismatched
hematopoietic stem cells are rejected by host NK cells
even in lethally irradiated mice (the so-called ‘‘hybrid
resistance model’’ [66]). Another effect may be a
reduction of 4T1 tumor-induced NK cell inhibitory ele-
ments like regulatory T cells and myeloid-derived sup-
pressor cells [63, 67–73], similar to its relevance for
disease-specific T-cell therapy [74].
What may the implications of our findings be for the
treatment of patients with metastasized breast cancer?
Adaptive transfer of alloreactive NK cells may at first
glance seem the most preferable therapy as it evades the
possible risks resulting from haploidentical HSCT like
GVHD and infections. The toxicity of adaptive NK cell
therapy in human patients is anticipated to be low based on
present-day experience, although the numbers of trans-
ferred NK cells were not as high as we would aim at based
on our dose–response experiment [75–77]. It remains to be
seen if the application of higher numbers of alloreactive
NK cells resulting in short-term engraftment will be as
curative as in our mouse model. Haploidentical HSCT from
NK-alloreactive donors and the subsequent application of
low-dose chemo-irradiation after NK cell repertoire matu-
ration is then an intriguing and promising treatment
approach as it results in the continuous production of
alloreactive NK cells in women with metastasized breast
cancer. When applicable, it may serve as a platform for
subsequent application of low-dose CY?TBI and/or other
immune-modulating treatments to enhance the alloreactive
NK cell effect.
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